Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Pediatric clinical trials play a major role in modern healthcare, as pediatric clinical trials are the only criteria to launch new drugs in the market for various indications that affect pediatric population and therefore, pharmaceutical and biotechnological industries have been gradually shifting from in-house clinical research to contract research organization (CRO).

There is significant product pipeline under clinical stage of development due to unmet medical needs for pediatric patient population. Robust drug development pipeline offer lucrative growth opportunities for the market in the near future. According to Pharmaceutical Research and Manufacturers Association (PHRMA) data in 2018. Moreover, in 2020, there are over 1,300 industry-sponsored pediatric clinical trials underway across a variety of therapeutic areas, including diseases where there is significant unmet need for treatment of infectious diseases, neurologic conditions, genetic disorders, and several forms of cancer.

The global pediatric clinical trials market size is estimated to be valued at US$ 12,571.7 million in 2020 and is expected to exhibit a CAGR of 9.0% over the forecast period (2020-2027).

Figure 1. Global Pediatric Clinical Trials Market Share (%), by Clinical Phase, 2020

Pediatric Clinical Trials  | Coherent Market Insights

Increasing demand for new vaccines and other biologic products to treat various infectious diseases such as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox, malaria, and streptococcal pharyngitis is expected to drive the market growth. According to the World Health Organization (WHO) 2018, globally, around 86% of infants are vaccinated against 26 diseases, however, 19.5 million children are unvaccinated leading to death of 2-3 million children annually. According to the Centers for Disease Control and Prevention (CDC) factsheet in 2018, around 470,000 children had active epilepsy in the U.S., which is estimated to be around 0.6% of children aged 0-17 years.

According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 463 million patients were suffering from diabetes worldwide in 2019. Of this, one million people (children and adolescents below 20 years of age) were suffering from type 1 diabetes.

Furthermore, rapidly rising children population is expected to propel demand for pediatric drug. Children represents 40% of world’s population, according to UN Population Prospect report in 2017. In 2016, there were around 74 million children younger than 18 years old in the U.S., accounting for 23% of the total population. The number of children in the country has grown since 1980, when there were 64 million children and is projected to continue to increase to 80 million in 2050, according to the U.S. Census Organization.

However, high termination percentage of pediatric clinical trials due to several reasons is expected to hinder growth of the pediatric clinical trials market. Pediatric trials have high percentage of failure due to reasons such as patient accrual. Other issues include behavioral problem and trial conduct issues such as inaccurate dosing, difficulty in formulation, and informative termination along with regulatory issues and drug toxicity during clinical trials. According to the U.S. FDA, around 25 - 40% of pediatric trials fail to establish safety, efficacy, and result in a labeled indication for pediatric use, which results in their termination.

request-sample

Pediatric Clinical Trials Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 12,571.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 9.0% 2027 Value Projection: US$ 22,993.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Clinical Trial Phase: Pre-clinical, Phase I, Phase II, Phase III.
  • By Study Design:
    • Interventional: Randomized Trial, Non-randomized Trial, Crossover Trial.
    • Observational
  • By Medical Condition: Neuropsychiatric Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive Diseases, Diabetes, Nutritional Deficiencies, Others.
Companies covered:

Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc

Growth Drivers:
  • Strong product pipeline, approval of new pediatric drugs, and increasing outsourcing for drug development by clients
  • Commercial tie-ups and acquisitions by key players
  • Innovation in clinical research and implementation of advanced technology
  • Increasing incidence of chronic diseases among the pediatric population
Restraints & Challenges:
  • Difficulty in conducting clinical trials for pediatric population
  • High termination rate of pediatric clinical trials due to various reasons

Global Pediatric Clinical Trials Market – Impact of Coronavirus (Covid-19) Pandemic

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in more than 14 million infected individuals worldwide as of 24 July 2020.

Furthermore, according to the Centers for Disease Control and Prevention, as of April 2, 2020, around 2,572 (1.7%) cases of COVID-19 were registered in patients younger than 18 years in the U.S.

Therefore, market players and research institutes are focusing on research and development activities by initiating clinical trials of drugs for the treatment of COVID-19 in children.

For instance, Gilead Sciences initiated phase 2/3 clinical trials in June 2020, to evaluate the safety, efficacy, tolerability, and pharmacokinetics of Remdesivir, an antiviral drug, in pediatric patients with coronavirus disease 2019 (COVID-19). The trial is estimated to be completed by December 2020.

Similarly, the University of Calgary initiated an observational study on March 18, 2020 to determine the clinical characteristics and outcomes of children potentially infected by COVID-19. The study is estimated to be completed by March 17, 2022.

Furthermore, research institutes are conducting observational studies to understand the impact of COVID-19 in various hospital departments.

For instance, the South Egypt Cancer Institute initiated an observational study on May 15, 2020 to determine the effect of the COVID-19 pandemic on effect on patients in the pediatric cancer care divisions in Egypt and the UAE. The study is estimated to be completed by May 15, 2021.

Figure 2. Global Pediatric Clinical Trials Market Value (US$ Mn), by Region, 2020

Pediatric Clinical Trials  | Coherent Market Insights

Increasing focus of CROs in the North America region on strategic mergers and acquisitions to expand the number of pediatric trials in the region is expected to drive the market growth in this region. For instance, in November 2018, Syneteract, a contract research organization based in North Carolina, acquired a niche CRO KinderPharm, focused on rare disease pediatric trials, in order to expand the pediatric trials footprint of Syneteract. In April 2018, KinderPharm LLC and Worldwide Clinical Trials formed a strategic alliance to develop the first single center of excellence for pediatric drug development and clinical research.

Followed by North America, Europe pediatric clinical trials market is expected to show significant growth during the forecast period, owing to increasing focus of organizations to facilitate pediatric drug development process. For instance, in May 2018, the members of the Collaborative Network for European Clinical Trials for Children/conect4children initiative, which include specialists from the University of Liverpool, Alder Hey Children’s NHS Foundation Trust (AHCNFT), and Liverpool Women’s NHS Foundation (LWNFT), announced a collaborative pediatric network to facilitate the development of novel drugs and therapies for the European pediatric population.

Key Players

Major players operating in the global pediatric clinical trials market include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.

Clinical trials generates evidence-based data and knowledge in medicine. Clinical trials conducted on children (between age group of 0 to 18) for research and development of drugs or formation of new drugs are called as pediatric clinical trials. Pharmaceuticals and biotechnological industries and government regulatory bodies are collectively focused on improving research and development for pediatric population. A new law in the U.S. and Europe was passed as pediatric regulation 2007 that required new adult drugs to be tested for use in children. This, in turn, is expected to lead to increasing number of pediatric clinical trials in the U.S. and worldwide.

Market Dynamics

Robust product pipeline, increasing approval of new pediatric drugs, and high outsourcing for drug development are major factors driving the pediatric clinical trials market growth. According to Pharmaceutical Research and Manufacturers’ Association (PHRMA) data in 2018, over 1,300 industry-sponsored pediatric clinical trials are underway across a variety of therapeutic areas, including diseases where there is significant unmet need such as infectious diseases, neurologic conditions, genetic disorders, and several forms of cancer. Similarly, 5 pediatric drugs received the U.S. FDA approval in 2018, and 4 and 7 in 2017 and 2015, respectively.

Moreover, introduction of new approaches in clinical research and implementation of advanced technology is expected to boost the market growth. Adoption of data analytics and machine learning platforms is expected to help in better management of the data generated during trials, which can play key role in faster drug development. For instance, in 2015, Quintiles announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution.

Increasing investment in the research and development by pharma and biotech companies targeting major chronic diseases such as cancer, cardiovascular disease, neuropsychiatry disease, and respiratory disease is expected to drive the market growth over the forecast period. According to a report published by the International Federation of Pharmaceutical Manufacturer and Association in 2017, pharmaceutical industry invested around US$ 149.8 billion on research and development, annually. The companies are downsizing this cost by outsourcing clinical research activities. There are more than 7,000 compounds in preclinical stage of development, out of which around 56 were launched in 2015 and around 225 new chemical and biological entities were launched between 2011 and 2015.

Key features of the study:

  • This report provides in-depth analysis of the global pediatric clinical trials market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pediatric clinical trials market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Syneos Health Inc., IQVIA Holdings, Inc., Charles River Laboratories International Inc., Covance Inc., ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global pediatric clinical trials market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric clinical trials market

Detailed Segmentation:

  • Global Pediatric Clinical Trials Market, By Clinical Trial Phase:
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
  • Global Pediatric Clinical Trials Market, By Study Design:
    • Interventional
      • Randomized Trial
      • Non-randomized Trial
      • Crossover Trial
    • Observational
  • Global Pediatric Clinical Trials Market, By Medical Condition:
    • Neuropsychiatric Conditions
    • Infectious Diseases
    • Maternal and Perinatal Conditions
    • Respiratory Diseases
    • Cardiovascular Diseases
    • Cancer
    • Digestive Diseases
    • Diabetes
    • Nutritional Deficiencies
    • Others
  • Global Pediatric Clinical Trials Market , By Region:
    • North America
      • By Clinical Trial Phase:
        • Pre-clinical
        • Phase I
        • Phase II
        • Phase III
      • By Study Design:
        • Interventional
          • Randomized Trial
          • Non-randomized Trial
          • Crossover Trial
        • Observational
      • By Medical Condition:
        • Neuropsychiatric Conditions
        • Infectious Diseases
        • Maternal and Perinatal Conditions
        • Respiratory Diseases
        • Cardiovascular Diseases
        • Cancer
        • Digestive Diseases
        • Diabetes
        • Nutritional Deficiencies
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Clinical Trial Phase:
        • Pre-clinical
        • Phase I
        • Phase II
        • Phase III
      • By Study Design:
        • Interventional
          • Randomized Trial
          • Non-randomized Trial
          • Crossover Trial
        • Observational
      • By Medical Condition:
        • Neuropsychiatric Conditions
        • Infectious Diseases
        • Maternal and Perinatal Conditions
        • Respiratory Diseases
        • Cardiovascular Diseases
        • Cancer
        • Digestive Diseases
        • Diabetes
        • Nutritional Deficiencies
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Clinical Trial Phase:
        • Pre-clinical
        • Phase I
        • Phase II
        • Phase III
      • By Study Design:
        • Interventional
          • Randomized Trial
          • Non-randomized Trial
          • Crossover Trial
        • Observational
      • By Medical Condition:
        • Neuropsychiatric Conditions
        • Infectious Diseases
        • Maternal and Perinatal Conditions
        • Respiratory Diseases
        • Cardiovascular Diseases
        • Cancer
        • Digestive Diseases
        • Diabetes
        • Nutritional Deficiencies
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Clinical Trial Phase:
        • Pre-clinical
        • Phase I
        • Phase II
        • Phase III
      • By Study Design:
        • Interventional
          • Randomized Trial
          • Non-randomized Trial
          • Crossover Trial
        • Observational
      • By Medical Condition:
        • Neuropsychiatric Conditions
        • Infectious Diseases
        • Maternal and Perinatal Conditions
        • Respiratory Diseases
        • Cardiovascular Diseases
        • Cancer
        • Digestive Diseases
        • Diabetes
        • Nutritional Deficiencies
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Clinical Trial Phase:
        • Pre-clinical
        • Phase I
        • Phase II
        • Phase III
      • By Study Design:
        • Interventional
          • Randomized Trial
          • Non-randomized Trial
          • Crossover Trial
        • Observational
      • By Medical Condition:
        • Neuropsychiatric Conditions
        • Infectious Diseases
        • Maternal and Perinatal Conditions
        • Respiratory Diseases
        • Cardiovascular Diseases
        • Cancer
        • Digestive Diseases
        • Diabetes
        • Nutritional Deficiencies
        • Others
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Clinical Trial Phase:
        • Pre-clinical
        • Phase I
        • Phase II
        • Phase III
      • By Study Design:
        • Interventional
        • Randomized Trial
        • Non-randomized Trial
        • Crossover Trial
        • Observational
      • By Medical Condition:
        • Neuropsychiatric Conditions
        • Infectious Diseases
        • Maternal and Perinatal Conditions
        • Respiratory Diseases
        • Cardiovascular Diseases
        • Cancer
        • Digestive Diseases
        • Diabetes
        • Nutritional Deficiencies
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Syneos Health Inc. *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • IQVIA Holdings, Inc.
    • Charles River Laboratories International Inc.
    • Covance Inc.
    • ICON plc.
    • Pharmaceutical Product Development, LLC.
    • Genentech (F. Hoffmann-La Roche AG).
    • Pfizer, Inc.
    • Bristol - Myers Squibb.
    • GlaxoSmithKline plc.
    • Sanofi S.A.
    • Novartis AG
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Takeda Pharmaceutical Company Limited.
    • Vertex Pharmaceuticals Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Clinical Trial Phase
      • Market Snippet, By Study Design
      • Market Snippet, By Medical Condition
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Collaborators For Pediatric Trial Network Studies
    • Incentives To Promote Pediatric Trial
    • Regulatory Scenario
    • Total Number Of Trials In the U.S. and Europe
    • List Of Pediatric Trials Registered In The U.S. (2019)
    • List Of Pediatric Trials Registered In Europe (2015-2019)
    • Overview Of Pediatric Trials Network (PTN) And List Of Trials Registered Under PTN
  4. Global Subcutaneous Drug Delivery Market, Impact of COVID-19 Pandemic
    • Post COVID-19 Impact
    • Initiatives Taken To Conduct Ongoing Clinical Trials
    • Clinical Trial Analysis
  5. Global Subcutaneous Drug Delivery Market, By Clinical Trial Phase, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
    • Segment Trends
      • Pre-clinical
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Phase I
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Phase II
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
      • Phase III
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Subcutaneous Drug Delivery Market, By Study Design, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Interventional Study
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Randomized Trials
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Non-randomized Trials
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
            • Crossover Trials
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Observational Study
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Pediatric Clinical Trials Market, By Medical Condition, 2020 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Neuropsychiatric Conditions
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Infectious Diseases
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Maternal and Perinatal Conditions
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Respiratory Diseases
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Cardiovascular Diseases
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Cancer
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Digestive Diseases
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Diabetes
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Nutritional Deficiencies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  8. Global Subcutaneous Drug Delivery Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Clinical Trial Phase, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Study Design, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Medical Condition, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Clinical Trial Phase, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Study Design, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Medical Condition, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Clinical Trial Phase, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Study Design, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Medical Condition, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Clinical Trial Phase, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Study Design, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Medical Condition, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Clinical Trial Phase, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Study Design, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Medical Condition, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Clinical Trial Phase, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Study Design, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Medical Condition, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Syneos Health Inc.*
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • IQVIA Holdings, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Charles River Laboratories International Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Covance Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ICON plc
        •  Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pharmaceutical Product Development, LLC
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Genentech (F. Hoffmann-La Roche AG)
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol - Myers Squibb
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vertex Pharmaceuticals Inc.
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

 *Browse 36 market data tables and 37 figures on "Global Pediatric Clinical Trials Market– Regional forecast to 2027”.

Frequently Asked Questions

The global pediatric clinical trials market size is estimated to be valued at US$ 12,571.7 million in 2020 and is expected to exhibit a CAGR of 9.0% between 2020 and 2027.
Strong product pipeline, approval of new pediatric drugs and increasing outsourcing for drug development by clients, commercial tie-ups and acquisitions by key players, and innovation in clinical research and implementation of advanced technology are driving growth of the global pediatric clinical trials market.
Phase III segment is estimated to hold major market share in the pediatric clinical trials market over the forecast period. Phase III clinical trial studies are used for drug approval from regulatory agencies such as FDA or EMA, which is expected to contribute for segment growth
Neuropsychiatric conditions segment is estimated to hold major market share in 2020, owing to increasing number of drug trials and approvals for neuropsychiatry conditions.
North America is estimated to generate highest revenue share in 2020 in the global pediatric clinical trials market during the forecast period.
Difficulty in conducting pediatric clinical trial due lack of pediatric participants, is a key factor hampering growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner